Embody vs Hims: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hims beats Embody overall, scoring 7.9/10 vs 7.3/10. Hims is more affordable at $175/mo vs $299/mo. Choose Embody for users looking for the lowest entry price with round-the-cloc. Choose Hims for men who want glp-1 access from a well-known, publicly traded.
A side-by-side comparison of Embody and Hims covering pricing, scores, medication types, insurance, and more to help you decide.
Embody
#31 of 40Compounded GLP-1 provider with 24/7 specialist support and competitive pricing for budget-conscious users.
Visit EmbodyHims
#12 of 40One of the largest and most recognized men's telehealth platforms in the US, offering compounded GLP-1 medications with a polished app experience and strong brand trust.
Visit Hims| Feature | Embody | Hims |
|---|---|---|
| Our Score | 7.3/10 | 7.9/10 |
| Starting Price | $299/mo | $175/mo |
| Medication Type | Compounded | Compounded |
| Insurance Accepted | No | No |
| Best For | Users looking for the lowest entry price with round-the-clock specialist support | Men who want GLP-1 access from a well-known, publicly traded telehealth brand |
| Ranking | #31 | #12 |
Pros & Cons Compared
Embody
Pros
- +$149 first month is one of the lowest entry prices in the GLP-1 market — includes medication, metabolic report, and 1:1 guidance
- +Oral tirzepatide gum format available — one of the few platforms offering a non-injectable tirzepatide option for needle-phobic patients
- +24/7 specialist support included at no extra cost for questions about dosing, side effects, and progress
- +Personalized metabolic report helps you understand your body's baseline before starting treatment
Cons
- −Monthly refill price jumps to $299/mo after the first month — nearly double what competitors like Mochi ($99/mo + membership) or TrimRx ($179/mo) charge
- −Compounded medications only — no brand-name Wegovy or Zepbound available through the platform
- −Limited company transparency — founding date, headquarters, and pharmacy partners are not publicly disclosed
Hims
Pros
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Polished app and web experience — one of the best user interfaces in men's telehealth
- +$199/mo all-inclusive for compounded semaglutide with consultations and free shipping
- +Massive brand recognition and extensive customer support infrastructure
Cons
- −Pivoted away from some compounded formulations after FDA crackdown — medication availability can shift
- −Compounded only — no brand-name Wegovy or Zepbound through the platform
- −Generic support experience — large patient volume means less personalized attention
- −Higher price than competitors like TrimRx ($179) or Enhance MD ($115) for a similar compounded product
Our Verdict
Hims edges out Embody with a score of 7.9/10 vs 7.3/10. If budget is your priority, Hims starts at $175/mo compared to Embody's $299/mo. Choose Embody if you want: users looking for the lowest entry price with round-the-clock specialist support. Choose Hims if you want: men who want glp-1 access from a well-known, publicly traded telehealth brand.